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OBJECTIVE: To estimate the patterns of medical care
and associated direct medical costs of managing chronic
hepatitis B virus (HBV) in France. METHOD: Five stages
were identiﬁed to describe the natural history of the
disease: Chronic hepatitis B without complications, com-
pensated cirrhosis, decompensated cirrhosis, hepatic
transplantation (ﬁrst and second year), and hepatocellu-
lar carcinoma. Standard care and corresponding items of
medical resources for these different states of health were
deﬁned on the basis of a literature review and the con-
clusions of an experts panel. Resources included ofﬁces
visits, procedures, laboratory tests, drugs (including
antiviral drugs), and hospitalizations. For each state, the
annual mean unit direct medical costs were estimated
using the weighted proportion of patients using the
resource. Unit costs (2001 value) were nationally avail-
able from the perspective of the French national insur-
ance. RESULTS: Approximately 24% of HBV patients
are managed with antivirals but these medications
accounted for approximately 45% and laboratory tests
for 30% of treatment costs in the chronic HBV state
(€1093). The mean annual treatment costs for the more
advanced disease states were: compensated cirrhosis
€1134, decompensated cirrhosis €8842 (due primarily to
hospital admissions), hepatic transplantation €84,568
(ﬁrst year) and €9147 (second year), and hepatocellular
carcinoma €9352. CONCLUSIONS: Treatment patterns
for HBV vary across centers in France. The average treat-
ment costs indicate a substantial ﬁnancial burden of HBV
that increases with advanced stages of the disease. Pre-
venting HBV or its advance could result in lowered long-
term treatment expenditures.
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OBJECTIVES: To estimate the prevalence and the quality
of life of subjects suffering from Herpes labialis (HL) in
the French population of adults above 17 years old.
METHODS: A population-based survey was conducted
among 10,000 adults through personal face to face inter-
views by using the quota sampling method (applied on
age, sex, economic working class and woman working
status). The screening was made by asking the subjects if
they have suffered from HL or if they have experienced
a fever blister, within the past 12 months. The quality of
life was assessed with the SF-36 questionnaire among 
the HL subjects identiﬁed and a control group of subjects
not suffering from HL (361 subjects). RESULTS: The
population surveyed was representative of the French
population in terms of age, sex, and geographic living
area. The annual prevalence of HL was estimated: 15.1%,
IC95%[14.1%; 16.1%]. The sex ratio women/men was
2/1 and the mean age was 41 years at the time of the study
versus 47.4 years in the control group (p < 0.01). Among
the HL population 14.2% experienced at least 6 recur-
rences in the past 12 months with a sex ratio women/
men at 3/1. The quality of life was worse in the HL 
population with at least 6 recurrences in the past 12
months than in the control group for both physical 
and mental health. After adjustment on age and sex, SF
36-scores were respectively 47.6 vs. 50.8 for physical
health (p < 0.05) and 45.3 vs. 47.9 for mental health (p
< 0.05). CONCLUSIONS: Herpes Labialis is a common
disease in France with an annual prevalence of 15% in
France. When occurring with at least 6 recurrences in 
the past 12 months, Herpes Labialis has a signiﬁcant
impact on quality of life, as measured by the SF-36 
questionnaire.
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OBJECTIVES: No measure has been available to assess
the impact of recurrent genital herpes (RGH) outbreaks.
Some herpes interventions attempt to abort an outbreak
or reduce its length and/or severity. An instrument was
required to determine the beneﬁt of such interventions
from the patients’ perspective, in the context of a clinical
trial. The objective was to develop a measure of the
impact of outbreaks using items representing functional
limitations of speciﬁc importance to RGH patients.
METHODS: Content was derived via interviews with
RGH patients (n = 40). Face & content validity of the
draft HOIQ were assessed by cognitive de-brieﬁng inter-
views with RGH patients (n = 19). Scaling/psychometric
properties were assessed via a web-survey, whereby par-
ticipants (n = 158) completed the HOIQ on two occa-
sions during an outbreak, with 24 to 72 hours between
administrations. RESULTS: Interviews revealed areas of
functioning affected during an outbreak to include; social,
work and other activities, relationships, personal hygiene,
choice of clothing, need to avoid becoming tired,
worry/anxiety and fear of discovery. De-brieﬁng inter-
views indicated that content was appropriate and the
measure easy to understand and complete. Rasch analy-
sis of survey data yielded a 12-item unidimensional
measure. Assessment of test-retest reliability was not pos-
sible due to rapid change in health status during an out-
break. However, item stability testing indicated that no
items exhibited time-related differential item functioning,
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indicating reproducibility. Internal consistency was good
(alpha: Time 1 = 0.87, Time 2 = 0.91). The HOIQ showed
evidence of discriminative validity, being able to distin-
guish between individuals who differed according to self-
reported severity of outbreak. CONCLUSIONS: The
HOIQ represents an effective method for determining the
impact of a herpes outbreak. The measure is scheduled to
be used on a daily basis during such outbreaks in a trial
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OBJECTIVES: Little is known about the health-related
quality of life (HRQL) in patients with primary antibody
deﬁciencies (PAD) and their need of lifelong im-
munoglobulin G (IgG) replacement therapy. Daly et al.
(1991) developed a questionnaire, the Life Quality Index
(LQI), consisting of one sale of 15 items related to IgG
treatment. The higher the score, the better the treatment-
speciﬁc HRQL. The construct validity has never been
shown, nor has the instrument been related to patient-
reported data. METHODS: Of 58 patients (17 children,
41 adults) with PAD were treated with weekly IgG infu-
sions (Beriglobin P, Aventis Behring, Marburg) for 10
months. Beside other instruments, the patients answered
the LQI and a single-item related to their change in health
status at baseline, 6- and 10-months. Construct validity
was evaluated using explorative factor analysis using the
Kaiser criterion and a varimax rotation. For the evalua-
tion of clinical validity an anchor-based approach was
applied, i.e. the patients’ self-assessments of their health-
status changes over time were related to LQI changes over
time. RESULTS: There was a noteworthy improvement
for 9 LQI items in adults and for 12 LQI items in chil-
dren from baseline to 10-months. Exploratory factor
analysis suggested a 3-factor solution that accounted for
52% of the total variance. For patients reporting an
improvement in their health status, all mean changes in
LQI scores were positive, and in 10 of 15 items changes
larger than 0.5 were observed. Thus, an improved 
self-perceived health led to improved LQI scores. CON-
CLUSION: The LQI is well suited to capture treatment-
speciﬁc aspects of HRQL in patients with PAD receiving
IgG. The items could be aggregated into three sub-scales.
The anchor-based approach indicates that the LQI may
serve as a valid instrument to assess the patients’ percep-
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OBJECTIVE: To evaluate the different European health
care structures involved in the care of Parkinson’s disease
(PD) as well as the economic impact of PD in European
countries (EC). METHODS: Data are generated by desk
top research (contacting national medical societies, PD
specialists, institutes for statistics, third party payers, 
ministries, support groups and conducting structured
database search). Reviewed data are: national treatment
guidelines and treatment patterns, hospitalization, reha-
bilitation, disease management programs and availability
of support groups. Epidemiologic data were elaborated
by systematic literature review. RESULTS: 1) In France
and the Czech Republic patients are mainly treated by
neurologists, while in Sweden patients are preferably
under care of General Practitioners. 2) Treatment guide-
lines are not standardized in Europe. 3) PD rehabilitation
is differently organized in the EC, however, paucity of
data precludes a detailed statement. United Kingdom
(UK) PD society is developing a network of PD specialist
nurses to co-ordinate multidisciplinary care, while in
Germany and other EC no disease management programs
exist. Total annual costs for PD differ: UK $280 million
(Haycock, 1995), France $411 million (LePen, 1999),
Sweden $136 million (Hagell, 2002) and Germany $1.0
billion (Dodel, 1998). Direct medical costs account for
20–40% of total costs depending on the Health care
system, indirect costs account for approximately 22–50%
of total costs in the UK (McMahon, 2000), Sweden
(Hagell, 2002), and Germany (Spottke, 2002), respec-
tively. Average length of stay differs among the EC
(Germany 21.1d, UK 29.4d, France 19d and Italy 16.4
d). CONCLUSION: PD care seems to be managed dif-
ferently in the EC analyzed. Despite the importance of the
disease detailed data are not easily accessible. One of the
aims of EuroPa is to gather this information and optimize
therapy for PD on an European level. These data are
crucial for a cost effective and optimized therapy for PD
patients.
